LadRx (NASDAQ:CYTR) Coverage Initiated at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of LadRx (NASDAQ:CYTRGet Rating) in a research report issued to clients and investors on Wednesday. The firm set a “hold” rating on the stock.

LadRx Price Performance

The firm’s fifty day simple moving average is $0.10. LadRx has a one year low of $0.05 and a one year high of $0.86.

LadRx Company Profile

(Get Rating)

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.

Featured Articles

Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.